VentriPoint Diagnostics Ltd V.VPT

RE:RE:Ventripoint submits VMS+4.0 for EU MDR approval 2024-10-11

[jopatclo]

jopatclo wrote: Now maybe Planning to be at the meeting in Toronto? MedTechConference2024 https://themedtechconference.com/ Any know Ventripoint ?(Planning to be at the meeting in Toronto?) The MedTech Conference in Toronto, Canada, October 15-17, 2024, will help you look ahead and create new possibilities. Featuring world-class speakers, a cross-cutting educational program, invaluable networking and next-level technology, this forum for transformational ideas is a can’t-miss event for the industry’s prominent and most promising companies.
 And this letter from Dr.Adams the visionary with Ventripoint

Dear Friend;
 

Attached is today’s news release.  Here is some background:

 

1. VMS+4.0 is a breakthrough product which allows for an automated analysis of 2D or 3D echocardiograms.

2. Automation is important right now as echocardiographers are pushed for time due to increasing numbers of cardiac patients due to the aging population and COVID.  The prediction is it is only going to get worse as more hearts damaged by COVID emerge.

3. Automation allows for faster analysis and less variability from operator to operator.  Unreliable analysis has been a concern with cardiologists since ultrasound began -if cannot trust the numbers, how do you decide a course of treatment?

4. The Company has a license to sell VMS+4.0 in Canada and now it has submitted all the information needed for approval for Europe.  Our previous submissions for VMS+1.0, 2.0 and 3.0 were approved fairly quickly in about 6-8 weeks and so if this holds for this submission, we should have approval November.  We will see.

5. We continue to support the basic VMS+3.0 and upgrade users to the advanced VMS+3.2, while we wait for approvals for the premium VMS+4.0.

6. We recently upgraded Seattle Children’s Hopsital to VMS+3.2 and you can watch Dr, Soriano speak about his experiences on a new video on our website (https://youtu.be/Ucu6uGRMtEs+) from the Take Heart conference.  Please take the time to listen to an expert’s opinion.

 

Thank you for your interest and support as we improve cardiac diagnostics for everyone everywhere and especially for children born with a heart defect.

 

Regards,

 

Dr. George Adams ICD.D

Executive-Chairman

Ventripoint Diagnostics Ltd.

TSXV-VPT

and this video 

• The Ollie Hinkle Foundation posted videos of their Take Heart 2024 conference on YouTube. In the first session Dr. Soriano of Seattle Children's Hospital provides a very nice overview of VMS+ and its benefits to patients and care providers.

  

  Take Heart 2024: Session 1

  youtube.com

Interesting see logo Ventripoint and Ascend Cardiovascular side by side on picture on the video =2:08:58 / 2:14:37 and see 2:09:11 / 2:14:37 = Special shout out & thank you to some of our partners! see logo Ventripont and Ascend Cardiovaslar on picture Take Heart 2024: Session 2 https://www.youtube.com/watch?app=desktop&v=Ucu6uGRMtEs

Good comment @hassy There are more near term catalysts on the horizon than 4.0- including more sales in EU, high profile sale in US etc. Market time is absolutely horrible for juniors in Canada and it has become a major distraction to Hugh's time. Instead of taking the "easy route" of diluting the existing shareholders with huge discount & large overhang, management team has shown respect to existing shareholders & chose to go with debenture financing converting at nil discount (at the time of announcement). Together with projected clearance of 4.0 and announce of sales, closing this CD should've been a slam dunk. Obviously with the delay in 4.0, and announcement of sales, this strategy has turned out to become a problem and in hindsight, maybe the "easy route" would've been better. In any case, very few insider of a junior would put in $500k of their own money to their company in this market condition. you should have some comfort in that.

and remenber on Ascend Cardiovascular The BEST automation and analysis of the PLANET GEN3EHO On the Ascend website https://ascendcv.com/ #vpt

Next Gnration Solution GEN3ECHO

interesting Read on GEN3ECHO 

& Remember  Hugh MacNaught “As more hospitals look to Ventripoint to provide advanced whole-heart analysis, this MDR submission is an important next step in the development and commercialization of the VMS+ family of devices” said Ventripoint President and CEO, Hugh MacNaught. “Upon approval we will be able to provide European cardiologists and care providers with one of the simplest, most-advanced, non-invasive heart-imaging tools available.” and on post Dr.Adams 

4. The Company has a license to sell VMS+4.0 in Canada and now it has submitted all the information needed for approval for Europe.  Our previous submissions for VMS+1.0, 2.0 and 3.0 were approved fairly quickly in about 6-8 weeks and so if this holds for this submission, we should have approval November.  We will see.

5. We continue to support the basic VMS+3.0 and upgrade users to the advanced VMS+3.2, while we wait for approvals for the premium VMS+4.0.

6. We recently upgraded Seattle Children’s Hopsital to VMS+3.2 and you can watch Dr, Soriano speak about his experiences on a new video on our website (https://youtu.be/Ucu6uGRMtEs+) from the Take Heart conference.